Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 172

1.
2.

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.

Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T; NASH Study Group.

Hepatology. 2010 Aug;52(2):472-9. doi: 10.1002/hep.23727.

PMID:
20683947
3.

Primary biliary cirrhosis in Lithuania: diagnosis and clinical picture.

Speiciene D, Irnius A, Leuschner U, Liakina V, Semuchiniene T, Barakauskiene A.

Med Sci Monit. 2007 Jul;13(7):CR299-306.

PMID:
17599023
4.

13C-methacetin and 13C-galactose breath tests can assess restricted liver function even in early stages of primary biliary cirrhosis.

Holtmeier J, Leuschner M, Schneider A, Leuschner U, Caspary WF, Braden B.

Scand J Gastroenterol. 2006 Nov;41(11):1336-41.

PMID:
17060128
5.

[Extrahepatic manifestations of liver diseases: skeleton].

Leuschner U.

Praxis (Bern 1994). 2006 Oct 4;95(40):1550-6. Review. German.

PMID:
17048413
6.

Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis.

Leuschner U, Manns MP, Eisebitt R.

Z Gastroenterol. 2005 Sep;43(9):1051-9. Review.

PMID:
16142614
7.

Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid.

Henzel K, Thorborg C, Hofmann M, Zimmer G, Leuschner U.

Biochim Biophys Acta. 2004 Feb 2;1644(1):37-45.

8.

Primary biliary cirrhosis--presentation and diagnosis.

Leuschner U.

Clin Liver Dis. 2003 Nov;7(4):741-58. Review.

PMID:
14594129
9.

The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study.

Leuschner M, Holtmeier J, Ackermann H, Leuschner U.

Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1369-76.

PMID:
12468960
10.

Drug therapy of primary biliary diseases: classical and modern strategies.

Schlichting J, Leuschner U.

J Cell Mol Med. 2001 Jan-Mar;5(1):98-115. Review. No abstract available.

11.

Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.

Holtmeier J, Leuschner U.

Digestion. 2001;64(3):137-50. Review.

12.

LUV's lipid composition modulates diffusion of bile acids.

Hofmann M, Schumann C, Zimmer G, Henzel K, Locher U, Leuschner U.

Chem Phys Lipids. 2001 Apr;110(2):165-71.

PMID:
11369325
13.

[Cholestatic hepatopathy: primary biliary cirrhosis].

Leuschner U.

Praxis (Bern 1994). 2000 Jun 15;89(24):1043-8. Review. German.

PMID:
10902460
14.

Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment.

Leuschner M, Dietrich CF, You T, Seidl C, Raedle J, Herrmann G, Ackermann H, Leuschner U.

Gut. 2000 Jan;46(1):121-6.

15.

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.

Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H, Happ J, Leuschner U.

Gastroenterology. 1999 Oct;117(4):918-25.

PMID:
10500075
16.

Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome.

Tsujii H, König J, Rost D, Stöckel B, Leuschner U, Keppler D.

Gastroenterology. 1999 Sep;117(3):653-60.

PMID:
10464142
17.

Peri-hepatic lymphadenopathy in primary biliary cirrhosis reflects progression of the disease.

Dietrich CF, Leuschner MS, Zeuzem S, Herrmann G, Sarrazin C, Caspary WF, Leuschner UF.

Eur J Gastroenterol Hepatol. 1999 Jul;11(7):747-53.

PMID:
10445795
18.

Small and large unilamellar vesicle membranes as model system for bile acid diffusion in hepatocytes.

Hofmann M, Zgouras D, Samaras P, Schumann C, Henzel K, Zimmer G, Leuschner U.

Arch Biochem Biophys. 1999 Aug 1;368(1):198-206.

PMID:
10415128
19.
20.

The effect of bile salts and calcium on isolated rat liver mitochondria.

Güldütuna S, Zimmer G, Leuschner M, Bhatti S, Elze A, Deisinger B, Hofmann M, Leuschner U.

Biochim Biophys Acta. 1999 Mar 30;1453(3):396-406.

Supplemental Content

Loading ...
Support Center